Amanote Research
Register
Sign In
First CDK 4/6 Inhibitor Heads to Market
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2015-028
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
February 23, 2015
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
To Cycle or Fight - CDK 4/6 Inhibitors at the Crossroads of Anti-Cancer Immunity
Clinical Cancer Research
Cancer Research
Oncology
Notch Targets the CDK Inhibitor Xic1 to Regulate Differentiation but Not the Cell Cycle in Neurons
EMBO Reports
Biochemistry
Genetics
Molecular Biology
This Little Chemistry Went to Market First.
Chemical and Engineering News
Chemical Engineering
Multiple CDK Inhibitor Dinaciclib Suppresses Neuroblastoma Growth via Inhibiting CDK2 and CDK9 Activity
Scientific Reports
Multidisciplinary
Management of Adverse Events During Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor-Based Treatment in Breast Cancer
Therapeutic Advances in Medical Oncology
Oncology
First Biosimilar Drug Set to Enter US Market
Nature
Multidisciplinary
Cooperating Oncogenes Converge to Regulate Cyclin/CDK Complexes.
Genes and Development
Genetics
Developmental Biology
Introduction to the Volume 4, First Issue
Journal of Interventional Gastroenterology
Figure 6: Details of Heads and Mouth Parts for Comparison.
